Agios Pharm Earnings Estimate

AGIO Stock  USD 30.86  0.07  0.23%   
The next projected EPS of Agios Pharm is estimated to be -1.76 with future projections ranging from a low of -1.93 to a high of -1.47. Agios Pharm's most recent 12-month trailing earnings per share (EPS TTM) is at 11.64. Please be aware that the consensus of earnings estimates for Agios Pharm is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Agios Pharm is projected to generate -1.76 in earnings per share on the 31st of March 2025. Agios Pharm earnings estimates show analyst consensus about projected Agios Pharm EPS (Earning Per Share). It derives the highest and the lowest estimates based on Agios Pharm's historical volatility. Many public companies, such as Agios Pharm, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Agios Pharm's earnings estimates, investors can diagnose different trends across Agios Pharm's analyst sentiment over time as well as compare current estimates against different timeframes. At this time, Agios Pharm's Gross Profit is very stable compared to the past year. As of the 17th of March 2025, Pretax Profit Margin is likely to grow to 20.66, while Operating Profit Margin is likely to drop (12.25).
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Agios Pharm Earnings Estimation Breakdown

The calculation of Agios Pharm's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Agios Pharm is estimated to be -1.76 with the future projection ranging from a low of -1.93 to a high of -1.47. Please be aware that this consensus of annual earnings estimates for Agios Pharm is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-1.74
-1.93
Lowest
Expected EPS
-1.76
-1.47
Highest

Agios Pharm Earnings Projection Consensus

Suppose the current estimates of Agios Pharm's value are higher than the current market price of the Agios Pharm stock. In this case, investors may conclude that Agios Pharm is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Agios Pharm's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of March 2025Current EPS (TTM)
975.43%
-1.74
-1.76
11.64

Agios Pharm Earnings per Share Projection vs Actual

Actual Earning per Share of Agios Pharm refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Agios Pharm predict the company's earnings will be in the future. The higher the earnings per share of Agios Pharm, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Agios Pharm Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Agios Pharm, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Agios Pharm should always be considered in relation to other companies to make a more educated investment decision.

Agios Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Agios Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-13
2024-12-31-1.63-1.74-0.11
2024-10-31
2024-09-301.11-2.42-3.53318 
2024-08-01
2024-06-30-1.6-1.69-0.09
2024-05-02
2024-03-31-1.65-1.450.212 
2024-02-15
2023-12-31-1.65-1.72-0.07
2023-11-02
2023-09-30-1.7-1.640.06
2023-08-03
2023-06-30-1.56-1.510.05
2023-05-04
2023-03-31-1.7-1.470.2313 
2023-02-23
2022-12-31-1.620.672.29141 
2022-11-03
2022-09-30-1.76-1.490.2715 
2022-08-04
2022-06-30-1.75-1.680.07
2022-05-05
2022-03-31-1.81-1.740.07
2022-02-24
2021-12-31-1.69-1.74-0.05
2021-11-03
2021-09-30-1.59-1.560.03
2021-07-29
2021-06-30-1.39-1.44-0.05
2021-04-29
2021-03-31-1.3226.9528.272141 
2021-02-25
2020-12-31-1.33-1.41-0.08
2020-11-05
2020-09-30-1.38-1.43-0.05
2020-07-30
2020-06-30-1.37-1.310.06
2020-04-30
2020-03-31-1.67-0.591.0864 
2020-02-13
2019-12-31-1.72-1.60.12
2019-10-31
2019-09-30-1.8-1.81-0.01
2019-08-01
2019-06-30-1.7-1.87-0.1710 
2019-05-02
2019-03-31-1.75-1.590.16
2019-02-14
2018-12-31-1.67-1.580.09
2018-11-01
2018-09-30-1.62-1.63-0.01
2018-08-02
2018-06-30-1.55-1.190.3623 
2018-05-04
2018-03-31-1.63-1.630.0
2018-02-14
2017-12-31-1.66-1.81-0.15
2017-11-01
2017-09-30-1.79-1.590.211 
2017-08-08
2017-06-30-1.56-1.78-0.2214 
2017-05-04
2017-03-31-1.71-1.560.15
2017-02-16
2016-12-31-1.51-1.340.1711 
2016-11-03
2016-09-30-1.52-1.63-0.11
2016-08-04
2016-06-30-0.48-1.47-0.99206 
2016-05-05
2016-03-31-0.79-0.610.1822 
2016-02-18
2015-12-31-0.5-1.08-0.58116 
2015-11-05
2015-09-30-0.88-1.07-0.1921 
2015-08-06
2015-06-30-0.46-0.85-0.3984 
2015-05-07
2015-03-31-0.92-0.130.7985 
2015-02-17
2014-12-31-0.58-0.76-0.1831 
2014-11-07
2014-09-30-0.520.10.62119 
2014-08-07
2014-06-30-0.4-0.54-0.1435 
2014-05-08
2014-03-31-0.37-0.39-0.02
2014-03-06
2013-12-31-0.34-0.4-0.0617 
2013-11-07
2013-09-30-0.29-0.47-0.1862 
2013-09-05
2013-06-30-0.32-2.8-2.48775 

About Agios Pharm Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Agios Pharm earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Agios Pharm estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Agios Pharm fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-148.9 M-156.4 M
Retained Earnings Total Equity-423.5 M-444.7 M
Earnings Yield 0.36  0.38 
Price Earnings Ratio 2.77  2.91 
Price Earnings To Growth Ratio(0.01)(0.01)

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving against Agios Stock

  0.42PFE Pfizer IncPairCorr
  0.41VRCA Verrica PharmaceuticalsPairCorr
  0.35ZVSA ZyVersa TherapeuticsPairCorr
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.64
Revenue Per Share
0.642
Quarterly Revenue Growth
0.511
Return On Assets
(0.20)
Return On Equity
0.5729
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.